


Telemedicine In Action: Transforming healthcare in LMICs



Webinar Topics and Dates

Sno	Date	Topic
1	06 March 2025	What is Telemedicine and How Are Health Systems Using It Globally? A Primer for Health System Leaders
2	10 April, 2025	Brick-and-mortar to Brick-and-click - Designing & Implementing Quality, Effective, and Impactful Telemedicine Programs
3	08 May, 2025	Evaluating telemedicine interventions: Evidence so far, and Methodologies
4	5 June, 2025	Creating a Telemedicine-Ready Healthcare Workforce: Training for Healthcare Providers
5	10 July, 2025	Telemedicine Policy: How Telemedicine is Regulated in Asia
6	7 August, 2025	Choosing a Telemedicine Software: The case for standards-compliant, interoperable & open-source Digital Public Goods (DPGs)
7	11 September, 2025	Ensuring Quality of Care & Patient safety in Telemedicine
8	9 October, 2025	Telemedicine Adoption by Communities - How Might We Drive Uptake of Telemedicine (TM) by Citizens?
9	6 November, 2025	Artificial Intelligence and Machine Learning in Telemedicine
10	11 December, 2025	Financing Telemedicine and ROI - The Business Case for Telemedicine
11	8 January, 2026	Telemedicine use cases to advance the SDGs - Part 1 Applications for Non-Communicable Diseases (Diabetes, Hypertension, Cardiovascular disease, Cancer and Mental Health)
12	5 February, 2026	Telemedicine uses to advance the SDGs - Part 2 Applications for Communicable Diseases (Tuberculosis, HIV)
13	12 March, 2026	Telemedicine use cases to advance the SDGs - Part 3 Applications for Primary Healthcare

Artificial Intelligence and Machine Learning in Telemedicine

Objectives and Outcomes

Objectives:

- Introduce participants to the use of AI/ML in telemedicine.
- Highlight current real-world use cases and innovations.
- Explore ethical, regulatory, and technical considerations for AI integration.

Expected Outcomes: By the end of the webinar, participants will:

- Gain a foundational understanding of how AI and ML are being applied in telemedicine.
- Why do we need AI and ML in telemedicine in order to address key challenges in the sustainability and scalability of telemedicine programs.
- Learn from case studies of AI-driven telemedicine solutions in LMICs.
- Understand the risks, limitations, and ethical challenges of using AI in healthcare.





Dr. Saif Khairat

Dr. Saif Khairat is the Beerstecher-Blackwell Distinguished Professor at UNC-Chapel Hill, and the principal investigator of the NIH-funded Center for Virtual Care Value and Equity (ViVE). Dr. Khairat is an expert in digital health who has authored over 100 publications, secured \$7.5M in funding, and is a digital health advisor to the WHO. He holds a PhD in Health Informatics and master's degrees in Computer Science and Public Health.



Ms. Divya Kamerkar

Divya Balaji Kamerkar is a visionary digital health entrepreneur committed to transforming women's sexual and reproductive healthcare through technology. As the Co-Founder and CEO of Pinky Promise, India's largest women's health platform that uses AI and great doctors to provide instant healthcare on a woman's fingertips. She blends her background as a biologist from Yale and an MBA from Wharton to create innovative, scalable, and accessible models of care. Her work harnesses AI and digital platforms to close healthcare gaps and empower women across India.



Dr. Neha Verma

Dr. Neha Verma is the Co-founder and CEO of Intelhealth, a telemedicine technology non-profit that delivers health services where there is no doctor. She is an entrepreneur and medical information engineer. She earned an MS in Applied Health Sciences and a PhD in Health Informatics from the Johns Hopkins University School of Medicine. Neha is also an active contributor for Women@Forbes, writing about women in tech, product development, organizational strategy, social impact and nonprofits.

Speaker I

Integration of ML & AI in Telehealth

Saif Khairat, PhD, MPH

Professor, University of North Carolina at Chapel Hill
Director, Center for Virtual Care Value and Excellence (ViVE)



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL



CENTER FOR VIRTUAL CARE VALUE AND EXCELLENCE

The Strategic Imperative : Bridging the Access Gap

Rural Access Gap

Roughly 50% live in rural areas, far from specialty care

Workforce Gap

Physician density -7 per 10,000 vs -16-17 globally

Disease Burden

Non-communicable diseases are a majority of mortality alongside infectious threats

Efficiency

Target AI where it extends reach and productivity toward UHC with safety and equity

Example (tele-triage hub): Village clinics send cases to a district telehealth hub; an AI triage bot prioritizes same-day video consults, reducing avoidable travel.

Sources: Rural access (regional context): [World Bank – Rural population \(% of total\), South Asia view](#) Physician density (global comparator; regional pages link to country detail): [WHO Data – Density of physicians \(per 10,000\)](#) NCD burden (SEARO): [WHO South-East Asia – Noncommunicable diseases \(regional facts\)](#) Telehealth at scale example for framing (national program): [eSanjeevani \(India\) overview in BMJ GH commentary](#)

AI in Telehealth



- **NCD** prevention in LMICs
- **Telemedicine solutions** for remote diagnosis and care.
- Chatbot-based tools to deliver personalized health information at scale.

How it works?

1. Prioritise condition/risk
2. Localise messages
3. Integrate with national systems
4. Monitor real-time KPIs

Source: <https://www.itu.int/en/ITU-D/ICT-Applications/Pages/mhealth-for-ncd-behealthy-bemobile.aspx>
<https://www.who.int/initiatives/behealthy>



Symptom checking and triage

ML and NLP Powered Chatbots

- Uses NLP to interpret patient-reported symptoms
- Uses ML to Triage
- Integrated into teleconsultation services in many countries (Germany, UK, USA, Singapore)

Impact: Improved Access, Improved Efficiency Reduces Physician Workload

- High Accuracy and safety^{1, 2}
- Potential to relieve pressure on Emergency Departments ³
- Potential to benefit the diagnostic efficacy of clinicians and improve quality of care.⁴





Four System Challenges

1

Data

Generalizability, sovereignty, privacy, and interoperability issues

2

Bias

Under-representation leading to errors for specific groups

3

Trust

Clinical validity and transparency concerns

4

Skills

Clinical, technical, and regulatory capacity gaps

These determine where AI succeeds or fails in telehealth.

❏ **Example (national tele-clinic):** Outcomes vary by language and handset quality, exposing intertwined data, bias, trust, and skills gaps to fix before scale.

Sources: Barriers to digital uptake (device, affordability, literacy, content): GSMA SOMIC hub <https://www.gsma.com/somic>

Challenge 1: Data

Generalizability risk

Models trained on non-local data underperform in new populations

Sovereignty, privacy, interoperability

cure, standards-based exchange

Fragmentation

Silos limit representativeness; invest in IDs, registries, consent, and FHIR profiles



- ❏ **Example (tele-ICU):** A risk model trained abroad underperforms on remote feeds; adding local telemonitoring data and retraining restores accuracy.

Sources: Generalizability & bias from training data: Obermeyer et al., Science (2019) Data governance/sovereignty anchor: WHO Global Strategy on Digital Health 2020–2025 Overview: <https://www.who.int/publications/i/item/9789240020924>

Challenge 2: Bias



Under-representation

Skin tone, language, demographics leads to errors for specific groups



Digital Divide

Without equity checks, AI widens the digital quality divide



Equity Checks

Require subgroup analyses pre-deployment and monitor after launch



Example (tele-dermatology): A photo-based service misses lesions in darker-skin patients; local images plus subgroup testing improve sensitivity.

Source: Dermatology disparities example (skin tones): Adamson & Smith, JAMA Dermatology (2018)



Challenge 3: Trust

Clinical validity needs independent, clinically relevant evaluation


Not vendor claims

Black-box concerns reduce adoption

Ensure fit-for-purpose transparency

Establish incident reporting

Escalation and rollback paths



- ❑ **Example (tele-triage line):** Add "why this advice" summaries, a clinical safety owner, and incident reporting; adherence and acceptance rise.

Source: Explainability & multidisciplinary view: Amann et al. BMC Med Inform Decis Mak (2020)

Challenge 4: Skills



Clinical

Train providers to interpret outputs and override when needed



Technical

Grow local data/AI engineering for tuning, validation, monitoring



Regulatory

Build authorities for review and post-market surveillance

- ❑ **Example (tele-ophthalmology network):** Nurses capture fundus photos; a "telehealth AI lead" and data team review flags weekly and retrain quarterly.

Sources:

Regulatory capacity & SaMD oversight: WHO (2023) Regulatory considerations on AI for health
ITU Focus Group background (precursor to GI-AI4H)

Turning Challenges into Opportunities : Four Opportunity



Scale

Extend reach to underserved populations



Speed

Accelerate diagnosis and triage using AI-based tools



Accuracy

Enhance clinical decision-making



Equity

Ensure inclusive access and outcomes

Map each to telehealth workflows.

- ❏ **Example (integrated telefront door):** AI triage (Scale), auto-intake notes (Speed), risk scores in e-visits (Accuracy), IVR in local languages (Equity).

Sources:

- Symptom checker accuracy vs GPs (vignettes): Gilbert et al., BMJ Open (2020)
- WHO digital interventions incl. client-to-provider & provider-to-provider telemedicine. health worker decision support: WHO Guideline (2019)

Opportunity: Scale

AI-based Triage and symptom advice

Manage primary-care flow and escalate urgent cases

Chronic NCD support

Always-on chatbot-based coaching and monitoring (with oversight)

Frontline worker aids

Standardize assessment and referral across villages

- ❏ **Example (community tele-visits):** CHWs use a tablet triage app; red-flag cases get same-day tele-consults; stable NCD patients receive tele-coaching and refills.

Sources:

- WHO recommendation to use CAD with chest radiography for TB screening (since 2021; updated 2025)
- Deep learning for diabetic retinopathy screening (multi-ethnic datasets): Ting et al., JAMA (2017)



AI in Telehealth: SAM

Opportunity : Speed

Locally hosted LLM based Chatbot for cancer coaching

Goal: Think, Reason, and Respond to support patients

- SAM's dynamically tailored responses are based on the user's persona and purpose
 - Doctor
 - Nurse
 - Pharmacist
- Trained on medical and scientific literature



Hello, I'm SAM, your Health Resource Chatbot! What can I help you with today?

Goal setting

Exercise plans

Information

Something else



CENTER FOR VIRTUAL CARE VALUE AND EXCELLENCE

Opportunity : Accuracy

Augment, not replace

AI-based Decision support
reduces cognitive load and
surfaces relevant data

Measure patient-relevant outcomes

Not just model metrics

Symptom checkers assist triage

Use as adjuncts with oversight



Example (tele-cardiology): During e-visits, an AI panel surfaces vitals, meds, and labs; fewer missed drug-disease interactions.

Sources: Digital inclusion barriers (device cost, literacy, relevant content); WHO Digital Health Guideline (equity considerations embedded in recommendations & implementation notes):



Opportunity : Equity



Bring specialist-level support to remote centers

Via telehealth plus AI, with subgroup monitoring



Multilingual and voice interfaces
For low-literacy settings, tested with intended users



Equity by design


Parity goals defined before scale-up



Example (maternal tele-line): Voice bots in local languages with low-literacy menus; AI flags danger signs and schedules nurse callbacks.

SAM: Health Assistant

- Handles everything from general health questions and consultations to diagnosis support and wellness guidance
- Personalized Personas
- Conversation history saved in the database
- Prepare patients pre-telehealth encounter



CENTER FOR VIRTUAL CARE VALUE AND EXCELLENCE

From Principles to Practice

Two Guides

WHO ethics and governance

Compass for autonomy, safety, equity, accountability, transparency, sustainability

UK buyer's/playbook approach

Checklists for problem definition, data readiness, evaluation, procurement, safety

- **Example (tele-triage pilot):** Map the pilot to ethics/governance checkpoints; adopt a buyer's checklist before expansion.

Sources: WHO (2021) Ethics and governance of AI for health
NHS AI Lab — A buyer's guide to AI in health and care "How to get it right"



WHO Guidance → Actionable Checkpoints



Human oversight

Clinician reviews outputs before action



Equity by design

Predefined subgroup thresholds and rollback criteria



Transparency

Clear capabilities, limits, and rationale in plain language



Accountability

Defined liability and incident reporting before deployment



Example (tele-derm safety case): Require human-in-loop review, patient notices, parity thresholds, and rollback triggers before scale.

Sources: HealthBench (LLM benchmark for health) MedPerf (federated benchmarking) Equity evaluation framework (HEAI) · Google Research explainer

UK Playbook → AI in Telehealth Template

1

Problem first

Clear clinical need and success metrics

2

Data readiness

Provenance, quality, privacy, representativeness

3

Efficacy and generalizability

External validation on local populations

4

Safety and regulation

Treat as SaMD where applicable; lifecycle monitoring

Action: create your buyer's guide with shared checklists and templates



Example (tele-procurement): Define the use case, verify data representativeness, require local external validation, specify post-market monitoring.

Benchmarking Efforts for AI in Health



Global Initiative on AI for Health (GI-AI4H).

- Launched in 2023
- long-term institutional structure,
- Mission: to enable, facilitate, and implement AI in healthcare.

Enable

Standards, governance, policies, and guidance on evidence-based AI4H


Facilitate

Pooled Investments & a global community of experts

Implement

Sustainable models of AI programs implementation at the country level

Coordination Engine



☐ **Example (regional tele-DR protocol):** Countries align a shared tele-retinopathy validation protocol, pool metrics, and publish a joint implementation note.

Source: WHO's Global Initiative on AI for Health (GI-AI4H). World Health Organization

References

1. Gilbert S, Mehl A, Baluch A, Cawley C, Challiner J, Fraser H, Millen E, Montazeri M, Multmeier J, Pick F, Richter C, Türk E, Upadhyay S, Virani V, Vona N, Wicks P, Novorol C. How accurate are digital symptom assessment apps for suggesting conditions and urgency advice? A clinical vignettes comparison to GPs. *BMJ Open*. 2020 Dec 16;10(12):e040269. doi: 10.1136/bmjopen-2020-040269. PMID: 33328258; PMCID: PMC7745523.
1. Gräf M, Knitza J, Leipe J, Krusche M, Welcker M, Kuhn S, Mucke J, Hueber AJ, Hornig J, Klemm P, Kleinert S, Aries P, Vuillerme N, Simon D, Kleyer A, Schett G, Callhoff J. Comparison of physician and artificial intelligence-based symptom checker diagnostic accuracy. *Rheumatol Int*. 2022 Dec;42(12):2167-2176. doi: 10.1007/s00296-022-05202-4. Epub 2022 Sep 10. PMID: 36087130; PMCID: PMC9548469.
1. Cotte F, Mueller T, Gilbert S, Blümke B, Multmeier J, Hirsch M, Wicks P, Wolanski J, Tutschkow D, Schade Brittinger C, Timmermann L, Jerrentrup A, Safety of Triage Self-assessment Using a Symptom Assessment App for Walk-in Patients in the Emergency Care Setting: Observational Prospective Cross-sectional Study: *JMIR Mhealth Uhealth* 2022;10(3):e32340 URL: <https://mhealth.jmir.org/2022/3/e32340> DOI: 10.2196/32340
1. Faqar-Uz-Zaman, Sara F. MD*; Anantharajah, Luxia MD*; Baumartz, Philipp MD*; Sobotta, Paula MD*; Filmann, Natalie MSc†; Zmuc, Dora MD‡; von Wagner, Michael MD§,||; Detemle, Charlotte MD*; Sliwinski, Svenja MD*; Marschall, Ursula MD¶; Bechstein, Wolf O. MD*; Schnitzbauer, Andreas A. MD*. The Diagnostic Efficacy of an App-based Diagnostic Health Care Application in the Emergency Room: eRadaR-Trial. A prospective, Double-blinded, Observational Study. *Annals of Surgery* 276(5):p 935-942, November 2022. | DOI: 10.1097/SLA.0000000000005614

Thank You!

Prof Dr Saif Khairat
saif@unc.edu



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL



CENTER FOR VIRTUAL CARE VALUE AND EXCELLENCE

Speaker II



<https://www.beautiful.ai/player/-OdMxylwY2sgb6GTecOb>

Speaker III



GenAI-enabled Digital Assistant: Improving the Accuracy and Efficiency of Clinical Diagnosis and Treatment Planning in rural Telemedicine





Ayu 2.0 – a GenAI enabled digital assistant

Differential Diagnosis (DDx)

Suggests top 5 possible diagnoses based on symptoms, vitals, and history.

Treatment Plan (TTx)

Recommends medications, tests, referrals, follow-up, and lifestyle tips, aligned with medical protocols.

Patient Story

Generates a quick, clear summary of the case for doctors to fast-track decision-making.

The screenshot displays the Ayu 2.0 digital assistant interface on a mobile device. At the top, the status bar shows the time as 11:59 and battery level at 69%. The patient's name, Jayashree Dhir, and age, F/47 Y, are displayed. The visit reason is listed as '2/4 Visit reason : Abdominal Pain'. The main question is 'How severe is the pain?' with the instruction 'Select any one'. The response options are 'Mild, 1-3', 'Moderate, 4-6' (which is selected), 'Severe, 7-9', and 'Very Severe, 10'. Below this, a progress indicator shows '8 of 12 questions'. The next question is 'What worsens the pain?' with the instruction 'Select one or more'. The response options are 'Hunger', 'Food' (selected), 'Urination', 'Pressure', 'Movement', 'Coughing', 'Straining', 'Other [describe]', 'None', and 'Don't know/Unsure'. A 'Submit' button is located at the bottom right of the form.

Development & Testing Approach

01

Benchmarking Datasets

- Curated test and training datasets

02

Evaluation Methodology

- Top-5 DDx accuracy (doctor-reviewed and LLM-validated)
- QUEST scoring

03

Model Testing

- Benchmarked 12 different AI models

04

Prompt Optimization

- DSPy
- In-context learning
- Few shot learning

05

Alternative Techniques
No improvement in accuracy

- Medically fine-tuned LLMs
- Reasoning-based models
- Reinforcement learning

Ayu Platform – Rules based history for patients & frontline health workers

The image displays three sequential screenshots of the Ayu Platform interface, showing the history-taking process for a patient named Jayashree Dhir (F/47 Y).

Screenshot 1 (11:58): The interface shows the patient's name and the visit reason: "2/4 Visit reason". A question asks, "What is the reason for this visit?" with a text input field and a search icon. Below, "Selected reasons" shows "Abdominal Pain" selected. "All reasons" lists "Abdominal Pain", "Abnormal Bleeding", "Animal bites & Insect stings", "Back & Neck pain", "Blood in stool or Black stool", "Breast complaints", and "Burns". Navigation buttons "Back" and "Next" are at the bottom.

Screenshot 2 (11:59): The visit reason is updated to "2/4 Visit reason : Abdominal Pain". A question asks, "How severe is the pain?" with options: "Mild, 1-3", "Moderate, 4-6" (selected), "Severe, 7-9", and "Very Severe, 10". Below, a question asks, "What worsens the pain?" with options: "Hunger", "Food" (selected), "Urination", "Pressure", "Movement", "Coughing", "Straining", "Other [describe]", "None", and "Don't know/Unsure". A "Submit" button is at the bottom right. A progress indicator shows "8 of 12 questions".


Screenshot 3 (12:03): The "Visit Summary" screen displays the collected information. The "Reason for visit" is "Abdominal Pain". The "Chief complaint(s)" section lists details: "Abdominal Pain", "Site - Upper (R) - Right Hypochondrium", "Pain radiates to - Right shoulder, Right scapula", "10 Days", "Onset - Gradual", "Timing - Increases after a meal", "Character of the pain - Colicky / Intermittent (comes & goes)", "Severity - Moderate, 4-6", "Exacerbating Factors - Food", "Relieving Factors - Vomiting, medications like Tramadol", "Prior treatment sought - None", and "Associated symptoms: Patient denies - Fever". The "Associated symptoms" section shows "Patient reports: No data added" and "Patient denies: No data added". Navigation buttons "Appointment" and "Send visit" are at the bottom.

250+ clinical protocols

15 languages

for history taking, physical examination and clinical decision support for common conditions.

Ayu Platform – Web Interface for Doctors



English ▾

Login

Login with your provided username and password then you can choose the verification method.

Username

doctor1

Password

.....



Next



Intelhealth [Terms & Conditions](#) and [Privacy Policy](#).

How do the Doctors make use of AI generated Differential Diagnosis

Diagnosis

Diagnosis type

Diagnosis status

• Diagnosis*

• Diagnosis type*

Primary

Secondary

• Diagnosis status*

Provisional

Confirmed

Under Evaluation

Cancel

Add

Ayu suggested diagnosis

Acute Hepatitis (Moderate-High likely)

Cholecystitis (Moderate likely)

Liver Abscess (Low-Moderate likely)

Pyelonephritis (Low likely)

Musculoskeletal Pain (Low likely)

Model	Top 1 DDx Accuracy	Top 5 DDx Accuracy
Gemini 2.5 Flash	67%	99%
Open AI GPT 4.1	54%	94%
LLama 4 Maverick 17B 128E	75%	98%

✓ The service is pluggable to these LLMs

1.Gemini 2.5 Flash

2.Open AI GPT 4.1

3.Llama 4 Maverick MOE 128 Experts

✓ The models have a contextualization layer on top of the base model to tune their outputs and safety-gate outputs

✓ The contextualization layer is trained on real-world telemedicine use data.

✓ **The system - base model + contextualization layer** is evaluated on carefully curated datasets from Intelhealth's telemedicine programs

DDx Interface In Ayu Platform

The screenshot displays the 'DDx Interface In Ayu Platform'. The top navigation bar includes 'Dashboard > Visit Summary' and a user profile 'Hello, rohith M s'. A vertical sidebar on the left contains icons for home, chat, calendar, and other functions. The main content area is titled 'Diagnosis' and features 'Ayu's Detailed Report'. A disclaimer states: 'This AI-generated suggestion is intended to support—not replace—your clinical judgment and may not account for all relevant factors; please use your own judgment before acting.' The report is organized into sections: 'Rationale' (with sub-sections for Acute Hepatitis, Cholecystitis, Liver Abscess, and Pyelonephritis) and 'Conclusion'. Each section lists clinical reasoning points and includes a 'Read more' link. The 'Conclusion' section summarizes the findings and suggests further investigations.

Dashboard > Visit Summary

Hello, rohith M s

Diagnosis

Ayu's Detailed Report

This AI-generated suggestion is intended to support—not replace—your clinical judgment and may not account for all relevant factors; please use your own judgment before acting.

Rationale

Acute Hepatitis (Moderate-High likely)

- Right upper quadrant pain, nausea, and fever are concerning for acute hepatitis.
- Hepatitis A and E are common in areas with poor sanitation, relevant to rural India.
- Acute hepatitis is liver inflammation caused by viruses, alcohol, drugs, or autoimmune diseases.

[Read more](#)

Cholecystitis (Moderate likely)

- Right upper quadrant pain is a key symptom of cholecystitis (gallbladder inflammation).
- Pain described as dull and aching, along with nausea, is consistent with cholecystitis.
- Cholecystitis is usually caused by gallstones blocking the cystic duct.

[Read more](#)

Liver Abscess (Low-Moderate likely)

- Fever and right upper quadrant pain could indicate a liver abscess.
- Liver abscesses are often caused by bacterial infections.
- Liver abscesses can be more common in areas with poor sanitation and hygiene.

[Read more](#)

Pyelonephritis (Low likely)

Conclusion

Considering the patient's presentation of right upper quadrant abdominal pain, fever, and nausea, the most likely diagnoses are acute hepatitis and cholecystitis. Further investigations, such as liver function tests, abdominal ultrasound, and complete blood count, are necessary to confirm the diagnosis and guide management. The possibility of a liver abscess should also be considered, especially in the context of rural India.

Medication prediction in Treatment Plan (TTx)

Dashboard > Visit Summary

Hello, rohith M s

Medication

Reminder: Patient is allergic to ibuprofen. Please prescribe accordingly.

Ayu suggested medication

This AI-generated suggestion is intended to support—not replace—your clinical judgment and may not account for all relevant factors; please use your own judgment before acting.

☐ Ondansetron 4 mg Oral Tablet (High)

- 1 tablet
- Twice daily
- 3 Days
- Before food

☐ Paracetamol 500 mg Oral Tablet (Moderate)

- 1 tablet
- Thrice daily
- 3 Days
- After food

☐ Bevon (Multivitamin) Oral Solution (Low)

- 5 ml
- Once daily
- 14 Days
- After food

☐ Lactulose 10 g/15 ml Oral Solution (Low)

- 15 ml
- Twice daily
- 7 Days
- After food

☐ Omeprazole 20 mg Oral Capsule (Low)

- 1 capsule
- Once daily
- 7 Days
- Before food

Investigations & Referrals Prediction in Treatment Plan (TTx)

Investigations

Ayu suggested investigations

 This AI-generated suggestion is intended to support—not replace—your clinical judgment and may not account for all relevant factors; please use your own judgment before acting.

☐ Liver Function Test (LFT)

☐ Hepatitis A IgM Detection Test

☐ HBsAg Test

Test

Add test to patient

Cancel

Add test

Referral

Ayu suggested referrals

 This AI-generated suggestion is intended to support—not replace—your clinical judgment and may not account for all relevant factors; please use your own judgment before acting.

☐ Medical Officer (MO), Primary Health Center (PHC), If LFT results are significantly abnormal or the patient's condition worsens, referral to a higher-level facility may be necessary.

Referral to

Referral facility

Priority of Referral

Remarks

Select or type



Select or type



Elective



Enter

Cancel

Save

Referral Prediction in Treatment Plan (TTx)

Dashboard > Visit Summary

Hello, rohith M s

Referral

Ayu suggested referrals

This AI-generated suggestion is intended to support—not replace—your clinical judgment and may not account for all relevant factors; please use your own judgment before acting.

☐ Medical Officer (MO), Primary Health Center (PHC), If LFT results are significantly abnormal or the patient's condition worsens, referral to a higher-level facility may be necessary.

Referral to	Referral facility	Priority of Referral	Remarks
Select or type	Select or type	Elective	Enter

Cancel

Save

Background and Rationale

Access to healthcare in India's rural and tribal regions remains limited due to geography, infrastructure gaps, and shortages of doctors.

Arogya Sampada, implemented by Intelhealth, uses telemedicine to extend medical consultations to underserved communities.

Clinicians delivering remote care often face challenges such as high patient loads, incomplete case histories, and limited diagnostic inputs, leading to variability in care quality.

Artificial intelligence (AI) offers an opportunity to strengthen these systems. Such tools could enhance diagnostic accuracy, consistency, and efficiency in telemedicine. However, evidence from real-world, low-resource settings remains scarce

Thus, this evaluation assessed the impact of integrating an AI-powered diagnostic assistant within *Arogya Sampada* on physicians' diagnostic accuracy, consultation time, and treatment quality.

Study Objectives

Objective

To evaluate the effect of large language model (LLM) assistance on diagnostic accuracy using a **randomized evaluation with a matched case-control design**, where each clinical case is reviewed once by an AI-assisted doctor and once by a non-assisted doctor.

Research Questions

- Does AI assistance optimised for enhancing diagnostic accuracy and treatment planning compared to clinicians using traditional and/or non-LLM-assisted resources?
- Does the AI assistance impact the time taken to diagnose?
- Does the AI assistance influence the clinical appropriateness and quality of prescriptions and treatment plans provided by clinicians?

Study Design

Hypothesis

LLM assistance improves diagnostic accuracy from 80% to 95%.

Statistical Parameters

- Outcome: Binary (correct vs incorrect diagnosis)
- Significance level (α): 0.05 (two-sided)
- Power ($1 - \beta$): 80%

Sample Size Calculation

Using the formula for matched-pair binary outcome studies:

$Z_{1-\alpha/2}$ is 1.96 for $\alpha = 0.05$

$Z_{1-\beta}$ is 0.84 for power = 80%

Odds Ratio (ψ) is 0.21

Required matched pairs according to McNemar's sample size calculation : 689

Final Case Requirements


- Each of the **10 pairs** will evaluate **100 unique clinical cases**
- Each case is seen by **2 doctors only** (one LLM-assisted, one without LLM assistance)
- Each doctor evaluates **100 cases**

Total cases=10 pairs× 100 =1000


$$N_{pairs} = \frac{\left(Z_{1-\alpha/2}(\psi+1) + Z_{1-\beta} \sqrt{(\psi+1)^2 - (\psi-1)^2 \pi_{discordant}} \right)^2}{(\psi-1)^2 \cdot \pi_{discordant}}$$

Study Design


Step 1: Creating a benchmarking dataset



Step 2: Recruiting study participants



Step 3: Randomizing cases and AI assistance



Study Design

Step 4: Completing consultations



Step 5: Evaluating case results

Independent clinicians' evaluation of case results



1. Consultation details captured
2. DDx Captured
3. Diagnosis and treatment plan captured

Overview of Evaluation Parameters and Scoring Methods


Parameter	Description
Diagnostic Accuracy	Binary: Correct if the clinician's diagnosis matched the ground truth; Incorrect otherwise.
Turn around time	Duration from case initiation to final submission, measured in minutes and seconds, available from the telemedicine platform.
Quality of Differential Diagnoses	Evaluated only in the LLM-assisted group; Top-5 Accuracy (whether Ground truth diagnosis present in top 5 + rank), Appropriateness*, Comprehensiveness*
Quality of Treatment Plan	Degree of alignment between clinician's plan and treatment plan based on ground truth diagnosis. Completeness* and Medical Appropriateness Index (MAI) as given by Hanlon et. al. (Hanlon, 1992)
Quality of Medical Tests	Relevance and necessity of investigations.*
Quality of Medical Advice	Clinical relevance, clarity, and safety of advice given.*
Quality of Referral Advice	Necessity and appropriateness of referral decisions or omissions.*

*Using a 5-point scoring scale (Bond, 2012; McDuff, 2025)

Key Findings

Quality of LLM generated DDx

Figure 3: Rank of The Ground Truth diagnosis in the LLM-generated Differential Diagnosis list




- The ground truth diagnosis appeared within the top three positions in 90.5% of cases, most commonly ranked first (70.7%), while only in 7.1% of cases it was not listed in the DDx.
- 90.8% of AI-generated DDx were rated as very appropriate, 4.8% as appropriate, and 4.4% as neutral, indicating a high overall standard of diagnostic relevance.

Key Findings

Diagnostic Accuracy

Figure 2: Comparison of Diagnostic accuracy Between Unassisted and AI-assisted groups.




Diagnostic accuracy was significantly higher with AI assistance (71.7%) compared to the unassisted group (59.7%), showing a 12% absolute improvement (N=1000, $\chi^2=39.34$, $p<0.001$).

Also noteworthy was that AI alone had the right diagnosis in the number 1 position **70.7%** of the time.

Key Findings

Time to diagnose

Figure 2: Comparison of Time taken Between Unassisted and AI-assisted arms.




The mean time taken was notably shorter with LLM support (2 minutes 25 seconds vs. 4 minutes 35 seconds), reflecting a 47% reduction.

Mean difference = 2.16 minutes i.e 2 minutes 10 seconds, $t(925)=12.15$, $p<0.001$.

Key Findings

Treatment Plan

Figure 4: Comparison of Medication Appropriateness Index (MAI) Between Unassisted and AI-assisted arms.



- Treatment plans developed with AI assistance demonstrated greater **completeness, with a median score of 4 (mean = 3.94 ± 0.01) compared to 3 (mean = 3.26 ± 0.01)** in the unassisted arm.
- The Medication Appropriateness Index (MAI), used to assess prescribing quality, was significantly lower (indicating higher appropriateness) in the **AI-assisted arm (mean = 1.07 ± 0.09)** than in the unassisted arm (mean = 2.29 ± 0.18).

Key Findings

Medical Test, Medical Advice and Referral Advice

Among 1000 cases, the appropriateness of medical recommendations was consistently higher in the unassisted arm across all domains. Notably, a higher proportion of unassisted responses received the top rating of 5 compared to the assisted group.

Table 1: Comparison of Appropriateness Scores for Medical Test, Medical Advice, and Referral Advice Between Unassisted and Assisted arms.

Appropriateness of (N=1,000):	Unassisted Score Mean (SE)	Assisted Score Mean (SE)	Unassisted: % Rated 5	Assisted: % Rated 5	p-value
Medical Test	4.47 (0.03)	3.86 (0.03)	78.30%	42.30%	< 0.001
Medical Advice	4.88 (0.02)	4.17 (0.05)	95.10%	70.50%	< 0.001
Referral Advice	4.80 (0.01)	4.53 (0.04)	90.50%	81.60%	< 0.001

Key Findings

Qualitative Insights: Clinicians' perceptions

The AI as a “Cognitive Co-Pilot”

“...it will remind us of the diseases we skip or we forget, so it will not let us make any human error.”

“But whatever I experienced, whatever we thought in our mind during making a diagnosis, it was already there in that your section, in provisional diagnosis and medication.”

“I usually go with my thought process... and then I cross-check if it's there or not in the diagnosis list.”

Key Findings

Qualitative Insights: Clinicians' perceptions

The “Reality Gap” of Context

"It will be better if you design it for a more complicated case."

"Some of the medications are not listed... so I have to give my own input."

Barriers to Widespread Adoption

"If there is training it is possible to use it regularly"

Key Learnings

Successes

- **Enhanced Performance:** AI significantly enhanced **diagnostic accuracy** and **efficiency** (reduced consultation time by nearly half), strengthening structured assessments.
- **Cognitive Co-Pilot:** Clinicians viewed the AI as a "cognitive co-pilot" that **validated reasoning** and **expanded diagnostic thinking**, not a replacement for judgment.
- **Proven Safety:** No unsafe or clinically inappropriate outputs were reported in the 1000 interactions, demonstrating the AI assistant is a **safe and valuable support tool**.

Areas for Refinement

- **Contextual Adaptation:** Need to further **train the model on locally relevant data**, building awareness of referral networks, infrastructure constraints, and context-specific clinical pathways.
- The primary design and deployment challenge is ensuring the model's outputs are aligned with **feasible options** and **local health realities**, not just ideal clinical standards.
- **Integration and Training:** Essential next steps include improving **integration within existing clinical workflows** and ensuring adequate **user training** before broader field deployment.

Limitations

- **Controlled & Retrospective Design:** The absolute diagnostic accuracy values should be interpreted with caution. Clinicians were diagnosing based only on written case vignettes and could not interact with patients or gather additional clinical context. These results therefore reflect performance under controlled, retrospective conditions rather than real-world teleconsultations.
- **Limited Contextual Familiarity:** Participants were **not directly embedded** in the communities represented, resulting in limited familiarity with local disease patterns, patient context, and health-system norms. This unfamiliarity may have affected the clinicians' ability to provide fully contextualized diagnoses and appropriate **referral decisions**.
- **AI Model's Contextual Gap:** Non-contextual AI suggestions may have **biased clinician decisions** toward ideal but locally irrelevant choices.

Way Forward

- **Deepen Analytical Understanding:** Conduct further analysis to assess how the quality and clinical depth of case information affects accuracy for clinicians in both the LLM and non-LLM arms.
- **Validate Performance In-Field:** Execute a prospective field study to better understand performance, integration, and safety in real-life settings, moving beyond controlled, retrospective vignettes.
- **Prioritize Contextual Model Training:** Ensure LLM suggestions align with feasible options and local realities, not just ideal clinical standards, to improve test and referral appropriateness.
- **Develop Integration & Training Strategy:** Focus on seamlessly integrating the AI into existing clinical workflows for maximum efficiency and adoption.



Thank you

Conclusion: Telemedicine Can Be A Crucial Role In LMIC's Through Transforming Health Equity



WHO SEARO + Intelhealth webinar series

www.intelehealth.org/webinars

Objectives:

Learn how telemedicine can address challenges and enhance health systems

Expected Outcomes:

By the end of the session, participants will:

- Gain a foundational understanding of telemedicine and its key components.
- Learn from successful case studies of national and sub-national public sector telemedicine implementations.
- Understand key policy and regulatory considerations for integrating telemedicine into national health systems.
- Be equipped with practical insights to explore and implement telemedicine solutions in your contexts.



Telemedicine in Action: Transforming healthcare for LMICs

Artificial Intelligence and Machine Learning in Telemedicine

November 6th, 2025, 14:00 IST

Context: AI and ML are reshaping telemedicine, offering new opportunities to enhance diagnostic accuracy, personalize care, and optimize system efficiency. However, applying AI responsibly in health settings demands thoughtful design, ethical safeguards, and practical understanding.

Objectives: Introduce participants to the use of AI/ML in telemedicine. Highlight current real-world use cases and innovations. Explore ethical, regulatory, and technical considerations for AI integration.

Expected Outcomes: By the end of the webinar, participants will:

- Gain a foundational understanding of how AI and ML are being applied in telemedicine.
- Why do we need AI and ML in telemedicine in order to address key challenges in the sustainability and scalability of telemedicine programs.
- Learn from case studies of AI-driven telemedicine solutions in LMICs.
- Understand the risks, limitations, and ethical challenges of using AI in healthcare.

LIST OF SPEAKERS



Dr. Neha Verma
Co-Founder and CEO
Intelhealth
Telemedicine technology non-profit
that delivers health services where
there is no doctor



Ms. Divya Kamerkar
Co-Founder and CEO
Pridy Promise Pvt. Ltd.
Providing affordable, quality, and
Digitized Care for Women — Anytime, Anywhere



Dr. Saif Khalirat
PhD, MPH
Professor of Digital Health and AI
Director of Center for VHS at UNC Chapel Hill

Click here to register for the webinar:
<http://bit.ly/42WXPuO>

For inquiries, please contact:
shalini@intelehealth.org
+91 9660982043

mehras@who.int
+91 89294 11772



Follow Us: [f](#) [in](#) Stay connected with us for updates:
[#TelemedicineThursdays](#)

Intelhealth

Hosted by:
World Health Organization
South-East Asia Region

Webinar Topics and Dates

Sno	Date	Topic
1	06 March 2025	What is Telemedicine and How Are Health Systems Using It Globally? A Primer for Health System Leaders
2	10 April, 2025	Brick-and-mortar to Brick-and-click - Designing & Implementing Quality, Effective, and Impactful Telemedicine Programs
3	08 May, 2025	Evaluating telemedicine interventions: Evidence so far, and Methodologies
4	5 June, 2025	Creating a Telemedicine-Ready Healthcare Workforce: Training for Healthcare Providers
5	10 July, 2025	Telemedicine Policy: How Telemedicine is Regulated in Asia
6	7 August, 2025	Choosing a Telemedicine Software: The case for standards-compliant, interoperable & open-source Digital Public Goods (DPGs)
7	11 September, 2025	Ensuring Quality of Care & Patient safety in Telemedicine
8	9 October, 2025	Telemedicine Adoption by Communities - How Might We Drive Uptake of Telemedicine (TM) by Citizens?
9	6 November, 2025	Artificial Intelligence and Machine Learning in Telemedicine
10	11 December, 2025	Financing Telemedicine and ROI - The Business Case for Telemedicine
11	8 January, 2026	Telemedicine use cases to advance the SDGs - Part 1 Applications for Non-Communicable Diseases (Diabetes, Hypertension, Cardiovascular disease, Cancer and Mental Health)
12	5 February, 2026	Telemedicine uses to advance the SDGs - Part 2 Applications for Communicable Diseases (Tuberculosis, HIV)
13	12 March, 2026	Telemedicine use cases to advance the SDGs - Part 3 Applications for Primary Healthcare

Webinar Evaluation and Feedback

Thank You for Attending!

Access the recording and slides at: <https://intelehealth.org/webinars/>

Please take a few minutes to fill out our feedback form – your input is invaluable!

<https://forms.gle/9bn92whEPArfRgHG6>



Q&A Session



Thank You For Joining Us!



www.intelehealth.org | sindhura@intelehealth.org , rishi@intelehealth.org, neha@intelehealth.org